Stock NAM NAMWIWAT MEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Namwiwat Medical Corporation

Equities

NAM

THB663010007

End-of-day quote Thailand S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
4.78 THB +0.84% Intraday chart for Namwiwat Medical Corporation -7.18% -31.22%
05-14 Namwiwat Medical Corporation Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-30 96,250,000 Shares of Namwiwat Medical Corporation Public Company Limited are subject to a Lock-Up Agreement Ending on 30-APR-2024. CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
NAMWIWAT MEDICAL CORPORATION Stock Namwiwat Medical Corporation
-31.22% 92.63M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.43% 181B
C+
MEDTRONIC PLC Stock Medtronic plc
+4.30% 114B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.09% 68.29B
A
DEXCOM, INC. Stock DexCom, Inc.
+5.86% 52.24B
B-
CENCORA, INC. Stock Cencora, Inc.
+8.15% 44.3B
B-
HOYA CORPORATION Stock Hoya Corporation
+6.67% 42.73B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+25.54% 32.52B
B
TERUMO CORPORATION Stock Terumo Corporation
+20.03% 26.02B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+1.00% 25.91B
A-
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. NAM Stock
  4. Ratings Namwiwat Medical Corporation